Tirzepatide
Compounded Dual GLP-1/GIP Receptor Agonist
A next-generation weight loss medication that targets two metabolic pathways, GLP-1 and GIP receptors, for enhanced appetite control, improved insulin sensitivity, and greater fat metabolism. In the SURMOUNT-1 trial, participants lost an average of 20–22% of body weight at the highest dose over 72 weeks when combined with lifestyle changes. Individual results vary.
Starting from $199 your first month
Then $299/mo all doses | Cancel Anytime | 3-Month $775 ($258/mo) | 6-Month $1,399 ($233/mo)
Frequency
Once Weekly
Rx Required
Yes, Prescribed Online
Pharmacy
US-Registered
Shipping
Free & Discreet
Tirzepatide at a Glance
How much does compounded tirzepatide cost per month? Through Madison Meds, compounded tirzepatide starts at $199 your first month, then $299 per month all doses, all-inclusive. There is no separate subscription fee, licensed-provider evaluation charge, or shipping charge on top of the monthly price.
Who is eligible for compounded tirzepatide? Adults with weight-related health considerations may be candidates. Eligibility is confirmed after a licensed-provider evaluation by an independent network of US-licensed providers who review your full health profile.
What is included in the monthly price? Licensed-provider evaluation, the compounded tirzepatide medication dispensed by a US-licensed compounding pharmacy, ongoing telehealth support, and free discreet shipping. Cancel anytime.
What is compounded tirzepatide? Compounded tirzepatide is the same active pharmaceutical ingredient found in FDA-approved brand-name tirzepatide products, dispensed by a US-licensed compounding pharmacy after a licensed-provider evaluation. It is prepared to the specifications set by the prescriber for the individual patient. Availability, formulations, and pricing differ from brand-name products.
How Tirzepatide Works
Tirzepatide is a first-in-class dual GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptor agonist. Unlike single-pathway medications, Tirzepatide activates two complementary metabolic systems simultaneously for more comprehensive weight management.
The GLP-1 pathway suppresses appetite by signaling satiety centers in the brain and slowing gastric emptying, keeping you fuller longer after meals. Meanwhile, the GIP pathway enhances metabolic efficiency, improves how your body processes fat, and supports healthier insulin responses.
This dual-action mechanism leads to greater appetite reduction and more significant fat loss than GLP-1 medications alone. Tirzepatide also helps the body use stored fat more effectively for energy, supporting gradual and sustainable weight loss when combined with lifestyle changes.
What Tirzepatide Can Do for You
Greater Average Weight Loss
In the SURMOUNT-1 clinical trial (published 2022), adults taking the highest tirzepatide dose lost an average of about 20–22% of body weight over 72 weeks alongside lifestyle changes. Individual results vary.
Dual-Pathway Action
Targets both GLP-1 and GIP receptors simultaneously for more comprehensive appetite control and metabolic support than single-pathway medications.
Improved Metabolic Health
Enhances insulin sensitivity, stabilizes blood sugar levels, and improves cholesterol and triglyceride profiles for better overall metabolic function.
Once-Weekly Injection
A single subcutaneous injection per week fits easily into any routine, no daily pills, no complicated schedules.
Physician-Monitored
Prescribed and supervised by a licensed US provider. Doses are carefully titrated based on your response and tolerance.
Sustained Energy
As metabolic function improves and excess weight decreases, many patients report more consistent energy levels throughout the day.
What to Expect
Week 1–4: Starting Low
Treatment begins at a low dose to allow your body to adjust. Most patients notice reduced appetite and fewer cravings within the first 2 weeks. Mild GI side effects are common but typically improve.
Week 4–12: Accelerating Results
Your dose is gradually increased on a monthly basis. Weight loss becomes more noticeable as the dual pathways work together. Appetite suppression strengthens and metabolic improvements begin.
Week 12+: Reaching Your Stride
At your target dose, consistent weight loss continues with well-managed hunger. Your provider monitors labs and adjusts as needed to optimize long-term results.
Tirzepatide Cost in 2026: What Every Channel Charges
Bottom line: Through Madison Meds, compounded tirzepatide is priced from $199 your first month, then $299 per month all doses, all-inclusive, compared to brand-name Zepbound at $1,086.37 per month or Mounjaro at $1,112.16 per month retail. Compare 2026 pricing across every channel below.
2026 Tirzepatide Cost by Channel
The short answer. In 2026, tirzepatide (the active ingredient in Mounjaro and Zepbound) is available at prices ranging from about $199 per month to over $1,100 per month depending on the channel. Brand-name Mounjaro carries a 2026 list price of $1,112.16 per month, and brand-name Zepbound pens list at $1,086.37 per month (RxIndex GLP-1 Tracker). Manufacturer self-pay through LillyDirect ranges from $299 to $499 per month for Zepbound vials or KwikPen (LillyDirect self-pay). Commercially insured patients using the Zepbound savings card can pay as little as $25 per month (Zepbound Savings Card). Through Madison Meds, compounded tirzepatide is available starting from $199 your first month, then $299 per month all doses, after a licensed-provider evaluation, with the medication dispensed by a US-licensed compounding pharmacy.
| Channel | 2026 Monthly Cost | What's Included | Eligibility |
|---|---|---|---|
| Madison Meds compounded tirzepatide | From $199 first month, then $299/mo all doses. 3-mo bundle $775 ($258/mo). 6-mo bundle $1,399 ($233/mo). | Licensed-provider evaluation, medication, ongoing telehealth support, free discreet shipping | Adults with weight-related health considerations; determined after licensed-provider evaluation |
| Mounjaro (brand, retail list) | $1,112.16/mo (source) | Medication only | FDA-approved for type 2 diabetes; requires provider prescription |
| Zepbound pens (brand, retail list) | $1,086.37/mo (source) | Medication only | FDA-approved for chronic weight management; provider prescription required |
| LillyDirect Zepbound vials (self-pay, 45-day refill) | $299/mo (2.5 mg), $399/mo (5 mg), $449/mo (7.5–15 mg) (source) | Medication only; vial format requires user to draw dose | US residents 18+ with valid prescription; refill within 45 days for lowest price |
| Zepbound KwikPen (self-pay via savings card) | $499/mo all doses (source) | Pre-filled pen device; medication only | Cash-pay patients; savings card expires Dec 31, 2026 |
| Zepbound with commercial insurance + savings card | As low as $25/mo, up to $100/fill (annual cap $1,300) (source) | Medication only | Commercial insurance that covers Zepbound; excludes Medicare, Medicaid, VA, TRICARE |
| Mounjaro savings card (with T2D diagnosis) | $25/mo, $1,950 annual cap (source) | Medication only | Requires type 2 diabetes diagnosis and commercial insurance; no self-pay option available |
| Compounded tirzepatide (market floor across telehealth providers) | From $199/mo advertised (source) When medication is priced this low, it commonly does not include a subscription or membership fee, and may reflect introductory rates, low-dose starter programs, or bulk multi-month prepay commitments that step up after the first month. | Varies by provider; commonly medication only. Provider evaluation, ongoing telehealth support, and shipping may be billed separately or require a paid subscription. | Varies; typically requires online evaluation by a licensed provider |
| Medicare Bridge Program (July 2026–Dec 2027) for Zepbound KwikPen | $50/mo flat (source) | Medication only | Medicare beneficiaries with BMI 27+ and obesity-related comorbidity |
Madison Meds vs. Other Compounded Tirzepatide Providers
Compounded tirzepatide pricing across telehealth providers varies widely once you look past the advertised starting price. Some providers tier pricing by dose, so climbing the titration ladder raises your monthly cost. Some charge a separate membership or subscription on top of the medication. Some require a commitment to a multi-month prepay to unlock the lowest price. Madison Meds keeps a single price across every dose, all-inclusive, with optional prepay bundles for patients who prefer to lock in savings.
| Provider | Monthly Price | Multi-Month Bundle | All-Inclusive? | Notes |
|---|---|---|---|---|
| Madison Meds | $199 first month, then $299/mo all doses | 3-mo $775 ($258/mo). 6-mo $1,399 ($233/mo). | Yes. No dose tiers. No subscription fee. | Provider evaluation, medication, ongoing telehealth support, and free discreet shipping all bundled into the price. Cancel anytime. |
| Henry Meds | ~$297/mo starter compounded tirzepatide (BestMedsHub 2026) | No published multi-month prepay bundle | Yes, at advertised price. Higher doses may cost more. | Reviewers report a range of $179 to $399 depending on dose and program. Injection-format program lists at $399 first month, $449 recurring (Innerbody). |
| Willow | $399 starter, $499 at 10-12.5 mg, $524 at 15 mg (AllyRx) | Not published as standard bundle pricing | Yes, but dose-tiered. Higher dose, higher price. | Patients who titrate to the maintenance 12.5 mg or 15 mg dose pay 25% to 31% more per month than the starter price (SeekPeptides). |
| Ro Body | $349 first month, $449 recurring monthly; ~$294/mo when purchased quarterly (RoenRx 2026) | Quarterly (3-mo) prepay unlocks the ~$294/mo rate | Yes. Ro membership included. | Brand Zepbound via LillyDirect through Ro ranges $299 to $499 per month depending on dose and refill cadence. |
| Mochi Health | $199/mo medication + $79/mo membership = $278/mo all-in (Mochi FAQ) | Membership billed monthly. No published multi-month medication bundle. | No. Medication and membership billed separately. | Advertised $199 is medication only. Required Mochi membership adds $79/mo (The Rx Index). Effective monthly cost is $278. |
Prices above reflect publicly advertised 2026 rates at the time of publication. Provider pricing changes frequently, and your own price at any provider may differ based on state, dose, program, or promotion. Verify directly with each provider before enrolling. Madison Meds keeps a single all-inclusive price across every dose in our program, and our prepay bundles are optional, not required.
Brand Tirzepatide: Mounjaro vs. Zepbound Pricing
Mounjaro and Zepbound are the two FDA-approved brand-name tirzepatide products from Eli Lilly. Both use the same molecule, but they carry different labeled indications and slightly different 2026 list prices. Mounjaro is approved for type 2 diabetes management, and its list price rose to $1,112.16 per month on January 1, 2026, up from $1,069.08 in 2025 (RxIndex). Zepbound is approved for chronic weight management and lists at $1,086.37 per month in pen format (RxIndex). These are the retail cash prices before any manufacturer program or insurance benefit is applied.
LillyDirect Self-Pay: The Manufacturer Cash Program
Eli Lilly offers a direct-to-consumer self-pay program for Zepbound only. Zepbound vials cost $299 per month for the 2.5 mg starter dose, $399 per month for 5 mg, and $449 per month for the 7.5 mg through 15 mg doses when patients refill on time within 45 days (JumpstartMD). If a refill lapses beyond 45 days, the price steps up to $499 and higher, up to $1,049 per month. The Zepbound KwikPen self-pay price is $499 per month for all doses via the manufacturer savings program (FindHonestCare). Mounjaro does not have a self-pay program; retail cash pricing is the only cash-pay path for that brand.
Savings Cards and Insurance Reality
Manufacturer savings cards can lower monthly costs meaningfully for the right patient. The Zepbound Savings Card brings monthly costs as low as $25 for commercially insured patients whose plan covers Zepbound, with a per-fill maximum of $100 and an annual cap of $1,300 (FindHonestCare). Patients whose commercial insurance does not cover Zepbound can still use the card, but the price becomes $499 per month with an annual cap of $8,060. The Mounjaro Savings Card offers $25 per month for patients with a type 2 diabetes diagnosis and commercial insurance, with a $1,950 annual cap. All manufacturer savings programs exclude Medicare, Medicaid, VA, and TRICARE beneficiaries and expire December 31, 2026.
The insurance reality. Most commercial insurance plans require prior authorization for tirzepatide and often deny coverage for weight management indications. Medicare does not cover GLP-1 medications for weight loss under Part D, although the new Medicare Bridge Program launched July 1, 2026 offers $50 per month for Zepbound KwikPen, Wegovy pen, Wegovy pill, and Foundayo for eligible Medicare beneficiaries with BMI 27 and above and an obesity-related comorbidity, running through December 31, 2027 (PeptideDeck). For most patients seeking tirzepatide for weight management outside these narrow paths, insurance is not a reliable option.
How Madison Meds Pricing Works
Through Madison Meds, compounded tirzepatide is available starting from $199 your first month, then $299 per month for all doses, after a licensed-provider evaluation by an independent network of US-licensed providers, with the medication dispensed by a US-licensed compounding pharmacy. Pricing is all-inclusive: the online evaluation, the medication, ongoing telehealth support with your provider, and free discreet shipping are all bundled into the monthly price. There are no separate consultation fees, no membership add-ons, and no shipping charges. If a licensed provider determines tirzepatide is not appropriate for your health profile, you are not charged for the evaluation. Compounded tirzepatide is not FDA-approved as a finished drug product; it is prepared per patient prescription by a US-licensed compounding pharmacy. Outcomes are individual, and results vary from person to person.
Who Tirzepatide Is For
Who qualifies: Adults with weight-related health considerations may be candidates for compounded tirzepatide. Final eligibility is determined after a licensed-provider evaluation by an independent network of US-licensed providers.
Eligibility & Candidate Criteria
Who is typically a good candidate. Tirzepatide may be considered for eligible adults with weight-related health considerations, such as high blood pressure, elevated blood sugar, or dyslipidemia. Adults with type 2 diabetes who need improved glycemic control alongside weight management are also candidates a licensed provider will evaluate. People who have struggled to maintain weight loss through lifestyle changes alone are often the population where tirzepatide may be appropriate after a licensed-provider evaluation.
The strongest responses tend to come from people who are consistent with weekly dosing, follow through on lifestyle changes alongside medication, and work with a provider to titrate dosing at the right pace.
Who may not be a good fit. Tirzepatide is not appropriate for everyone. People with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN2) should not take it. It is not recommended during pregnancy or while breastfeeding. People with a history of pancreatitis, severe gastrointestinal disease, or diabetic retinopathy may need an alternative approach.
After a licensed-provider evaluation by an independent network of US-licensed providers, a provider will assess whether tirzepatide may be appropriate based on your full health picture. If it is not, you will not be charged for the evaluation. Outcomes are individual, and results vary from person to person.
Side Effects & Drug Interactions
Understanding the full safety profile of tirzepatide helps you make an informed decision and know what to watch for during treatment. This section is educational content, not medical advice. Please discuss your individual risk factors with a licensed provider.
Common side effects and how to manage them. The most frequently reported side effects of tirzepatide are gastrointestinal and are typically mild to moderate, often improving as your body adjusts to each dose:
- Nausea is the most common, especially early in treatment and after each dose step-up. It typically fades within days as your body adjusts. Tips: inject at night, eat smaller meals, and avoid fatty or heavily processed foods around injection day.
- Diarrhea is common with tirzepatide, particularly in the first weeks. Staying hydrated and easing back on high-fat meals usually helps.
- Constipation also occurs and is often underreported. Water, adequate fiber, and gentle daily movement help.
- Vomiting can occur, particularly with large or rich meals. Eat slowly and stop when full.
- Decreased appetite and stomach discomfort are expected as tirzepatide works. Mild bloating and abdominal discomfort are generally transient.
- Fatigue is occasionally reported, especially in early weeks and after dose increases.
When to contact your provider. Reach out promptly if you experience persistent or severe abdominal pain (especially radiating to the back), significant or persistent vomiting, signs of low blood sugar if you also take diabetes medications, a lump or swelling in your neck, hoarseness or difficulty swallowing, vision changes if you have a history of diabetic retinopathy, or signs of a serious allergic reaction.
Drug interactions worth noting. Tirzepatide slows gastric emptying, which can affect the absorption timing of oral medications, including certain thyroid medications and oral contraceptives. Tirzepatide used alongside insulin or insulin-stimulating medications may increase the risk of hypoglycemia. Provide a complete list of medications, supplements, and health conditions during your intake evaluation so any interactions can be flagged.
Boxed warning context. Tirzepatide carries a boxed warning related to thyroid C-cell tumors observed in animal studies. The relevance of these findings to humans is not established, but tirzepatide is contraindicated in people with a personal or family history of medullary thyroid carcinoma or MEN2.
This is educational content, not medical advice. A licensed provider will review your full health history during your evaluation to assess whether tirzepatide may be appropriate given your specific risk profile.
Important Safety Information
Compounded tirzepatide is not FDA-approved as a finished drug product. It is prepared by a US-licensed compounding pharmacy under a prescription from an independent network of US-licensed providers. Common side effects include nausea, diarrhea, decreased appetite, vomiting, and constipation, most are mild and improve with dose titration.
Tirzepatide should not be used by individuals with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. Not recommended during pregnancy or breastfeeding. Always consult your healthcare provider.
Ready to take the next step?
Complete a brief online evaluation to see if Tirzepatide is right for you. A licensed provider will review your health profile and create a personalized plan.
FAQ